Amador Bioscience: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Amador Bioscience
Largest movements
- Cash +€435,459
up €435,459 (+318.7%), from €136,648 to €572,106
mainly Debts after one year (+€2.8m) and Trade debts (+€566,173)
- Receivables within one year +€360,252
up €360,252 (+155.6%), from €231,465 to €591,717
of which Trade receivables: +€451,677
- Tangible fixed assets -€35,566
down €35,566 (-74.1%), from €48,005 to €12,438
of which Furniture and vehicles: -€33,942
- Debts after one year +€2.8m
new in 2025: €2.8m
- Other debts -€2.7m
no longer reported in 2025 (was €2.7m)
- Trade debts +€566,173
up €566,173 (+827.2%), from €68,445 to €634,618
- Profit (loss) carried forward +€267,760
up €267,760 (+9.9%), from -€2.7m to -€2.4m
- Tax, wage and social debts -€132,224
down €132,224 (-60.2%), from €219,740 to €87,516
of which Remuneration and social security: -€83,240
- Gross operating margin +€2.5m
up €2.5m, from -€201,554 to €2.3m
- Write-downs +€1.5m
new in 2025: €1.5m
- Staff costs -€126,077
down €126,077 (-21.2%), from €594,757 to €468,680
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €456,270 | €1,216,414 | +€760,144 | +166.6% |
| Fixed assets | 21/28 | €85,905 | €50,338 | -€35,566 | -41.4% |
| Tangible fixed assets | 22/27 | €48,005 | €12,438 | -€35,566 | -74.1% |
| Furniture and vehicles | 24 | €36,234 | €2,292 | -€33,942 | -93.7% |
| Other tangible fixed assets | 26 | €11,771 | €10,147 | -€1,625 | -13.8% |
| Financial fixed assets | 28 | €37,900 | €37,900 | = | 0.0% |
| Current assets | 29/58 | €370,365 | €1,166,075 | +€795,710 | +214.8% |
| Amounts receivable within one year | 40/41 | €231,465 | €591,717 | +€360,252 | +155.6% |
| Trade receivables | 40 | €139,978 | €591,656 | +€451,677 | +322.7% |
| Other amounts receivable | 41 | €91,487 | €61 | -€91,426 | -99.9% |
| Cash at bank and in hand | 54/58 | €136,648 | €572,106 | +€435,459 | +318.7% |
| Deferred charges and accrued income | 490/1 | €2,252 | €2,252 | = | 0.0% |
| Total equity and liabilities | 10/49 | €456,270 | €1,216,414 | +€760,144 | +166.6% |
| Equity | 10/15 | -€2,596,825 | -€2,329,065 | +€267,760 | +10.3% |
| Contributions | 10/11 | €100,000 | €100,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€2,696,825 | -€2,429,065 | +€267,760 | +9.9% |
| Amounts payable | 17/49 | €3,053,095 | €3,545,479 | +€492,384 | +16.1% |
| Amounts payable after more than one year | 17 | - | €2,807,860 | +€2.8m | |
| Financial debts | 170/4 | - | €2,807,860 | +€2.8m | |
| Amounts payable within one year | 42/48 | €3,037,610 | €722,133 | -€2.3m | -76.2% |
| Trade debts | 44 | €68,445 | €634,618 | +€566,173 | +827.2% |
| Suppliers | 440/4 | €68,445 | €634,618 | +€566,173 | +827.2% |
| Taxes, remuneration and social security | 45 | €219,740 | €87,516 | -€132,224 | -60.2% |
| Taxes | 450/3 | €109,209 | €60,225 | -€48,984 | -44.9% |
| Remuneration and social security | 454/9 | €110,531 | €27,291 | -€83,240 | -75.3% |
| Other amounts payable | 47/48 | €2,749,425 | - | -€2.7m | |
| Accrued charges and deferred income | 492/3 | €15,485 | €15,485 | = | 0.0% |
| Remuneration, social security and pensions | 62 | €594,757 | €468,680 | -€126,077 | -21.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €15,353 | €10,415 | -€4,938 | -32.2% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | - | €1,512,740 | +€1.5m | |
| Other operating charges | 640/8 | €4,508 | €62 | -€4,446 | -98.6% |
| Non-recurring operating charges | 66A | €79,008 | €20,152 | -€58,856 | -74.5% |
| Gross operating margin | 9900 | -€201,554 | €2,282,265 | +€2.5m | |
| Operating profit (loss) | 9901 | -€895,179 | €270,216 | +€1.2m | |
| Financial income | 75/76B | €1 | €531 | +€530 | +84150.8% |
| Recurring financial income | 75 | €1 | €531 | +€530 | +84150.8% |
| Financial charges | 65/66B | €4,109 | €2,724 | -€1,385 | -33.7% |
| Recurring financial charges | 65 | €4,109 | €2,724 | -€1,385 | -33.7% |
| Profit (loss) for the period before taxes | 9903 | -€899,288 | €268,023 | +€1.2m | |
| Income taxes | 67/77 | €431 | €263 | -€169 | -39.1% |
| Profit (loss) for the period | 9904 | -€899,719 | €267,760 | +€1.2m | |
| Profit (loss) for the period to be appropriated | 9905 | -€899,719 | €267,760 | +€1.2m |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 4 October 2026 via checked.be.